Real-world watch on CMV drugs in transplant patients

NCT ID NCT04690933

Completed Knowledge-focused Sponsor: University Hospital, Limoges Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated May 14, 2026 · Updated 18 times

Summary

This study followed 400 stem cell transplant recipients to see how well newer anti-CMV drugs work in everyday practice and whether the virus becomes resistant. Researchers tracked infections, drug side effects, and survival. The goal is to improve treatment guidelines for high-risk patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

APHP

Paris, France
CHU

Amiens, France
CHU

Angers, France
CHU

Besançon, France
CHU

Bordeaux, France
CHU

Caen, France
CHU

Clermont-Ferrand, France
CHU

Grenoble, France
CHU

Montpellier, France
CHU

Nancy, France
CHU

Poitiers, France
CHU

Rouen, France
CHU

Saint-Etienne, France
CHU

Strasbourg, France
CHU de LIMOGES

Limoges, Limoges, 87045, France
HCL

Lyon, France

Conditions

Explore the condition pages connected to this study.

ANTIVIRAL DRUG RESISTANCE ANTIVIRALS ANTIVIRALS CYTOMEGALOVIRUS INFECTIONS HEMATOPOIETIC STEM CELL TRANSPLANTATION HEMATOPOIETIC STEM CELL TRANSPLANTATION